Back

Latest Forum Topics / Others

Post Reply

Vicplas Post Reply Rate topic
josephyeo Elite	30-Jan-2020 21:36        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	3+1 main reasons why i am vested in this counter: 1. excellent dividend yield full year dividend 0.75 cts, price 9.0 cts ... yield 8.3% 2. low valuation on profit of $4.2 mil against market cap of $45.6 mil, the p/e is 10.8 X. This is relatively low considering the fact that it has a growing medical devices sector n its high dividend yield 3. its likely to be a growth company Its efforts in the expansion of the medical devices segment seem to bear fruits. It has widened its customer base, introduce more products and gone into more segments of the medical industry. Example, they are now in Airway Management, Respiratory, Endoscopy, Drug Delivery and Vascular. Its also in different locations. 4. wuhan virus the wuhan virus is actually an add-on. I was already keen in the counter before the wuhan virus issue, As company is thinly traded, this counter is not for punters/traders. Its more for long term holder or dividend investors. Just sharing. Dyodd
Useful To Me  Not Useful To Me
josephyeo Elite	29-Jan-2020 23:16        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	Fairly good volume today ... 564 lots traded. Closed at 11.5 cts. There is a good chance that volume will pick up further. Just my feelings. josephyeo      ( Date: 29-Jan-2020 13:33) Posted: As can be seen below, the company is well positioned in China n in the relevant segments also, that is: Airway Management n Respiratory segment. Demand for Vicplas products are likely to surge given the current health issues in Wuhan. A quote from company' s annual report: The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries, - Forefront Medical Technology (Pte) Ltd and - Forefront Medical Investment Pte. Ltd. in Singapore - Forefront (Xiamen) Medical Devices Co., Ltd and - Forefront Medical Technology (Jiangsu) Co., Ltd in China - and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore. A quote from 1st half financial report: full medical devices for an increasing number of medical industry segments such as - Airway Management, - Respiratory, Endoscopy, - Drug Delivery and - Vascular. Also, the segment has shown substantial depth of experience and expertise that gives its global customers the confidence to place orders with it for the manufacturing of their medical devices. Just sharing. Dyodd
Useful To Me  Not Useful To Me
josephyeo Elite	29-Jan-2020 13:33        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	As can be seen below, the company is well positioned in China n in the relevant segments also, that is: Airway Management n Respiratory segment. Demand for Vicplas products are likely to surge given the current health issues in Wuhan. A quote from company' s annual report: The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries, - Forefront Medical Technology (Pte) Ltd and - Forefront Medical Investment Pte. Ltd. in Singapore - Forefront (Xiamen) Medical Devices Co., Ltd and - Forefront Medical Technology (Jiangsu) Co., Ltd in China - and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore. A quote from 1st half financial report: full medical devices for an increasing number of medical industry segments such as - Airway Management, - Respiratory, Endoscopy, - Drug Delivery and - Vascular. Also, the segment has shown substantial depth of experience and expertise that gives its global customers the confidence to place orders with it for the manufacturing of their medical devices. Just sharing. Dyodd
Useful To Me  Not Useful To Me
josephyeo Elite	29-Jan-2020 11:04        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	The point is ... they were not prepared or did not expect such health issues to happen. Since that is the case, they are unlikely to have enough stocks. They was no reasons to keep stocks. Its only after it happen that they realise they need more stocks. It would be quite ridiculous for them to keep stocks of medical devices when they obviously did not need it under normal circumstances. Just my views. Casilb      ( Date: 29-Jan-2020 10:03) Posted: They build new hospitals so maybe will have abit of demand?
Useful To Me  Not Useful To Me
Casilb Master	29-Jan-2020 10:03        Casilb About Contact  Quote this Post!
x 0   x 0  Alert Admin	They build new hospitals so maybe will have abit of demand?
Useful To Me  Not Useful To Me
josephyeo Elite	29-Jan-2020 09:56        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	For a health issue as large as the current epidemic/pandemic I am quite sure that the demand for all related needs are in short supply, maybe some more n some less. Even hospital beds are short. Just my thoughts.
Useful To Me  Not Useful To Me
Trader-101 Supreme	29-Jan-2020 09:35        Trader-101 About Contact  Quote this Post!   Mood: Yells: "Don't trust what i say, Trust your decisions. "
x 0   x 0  Alert Admin	Just a opinion from me, If I am not wrong this company produces Medical devices but currently China crisis is not short of medical devices, they are just short of medical disposable items such as masks medical aprons gloves etc. so Wuhan virus is not benefitting this directly, maybe the aftermath of it will. However this might just be one of the pennies joining the rally. josephyeo      ( Date: 28-Jan-2020 16:44) Posted: Demand for Vicplas products are likely to surge given the current health issues in Wuhan. A quote from company' s annual report: The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries, - Forefront Medical Technology (Pte) Ltd and - Forefront Medical Investment Pte. Ltd. in Singapore - Forefront (Xiamen) Medical Devices Co., Ltd and - Forefront Medical Technology (Jiangsu) Co., Ltd in China - and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore. A quote from 1st half financial report: full medical devices for an increasing number of medical industry segments such as - Airway Management, - Respiratory, Endoscopy, - Drug Delivery and - Vascular. Also, the segment has shown substantial depth of experience and expertise that gives its global customers the confidence to place orders with it for the manufacturing of their medical devices. Just sharing. Dyodd
Useful To Me  Not Useful To Me
josephyeo Elite	29-Jan-2020 08:19        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	!st half results will be out around March 2020.
Useful To Me  Not Useful To Me
josephyeo Elite	28-Jan-2020 16:44        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	Demand for Vicplas products are likely to surge given the current health issues in Wuhan. A quote from company' s annual report: The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries, - Forefront Medical Technology (Pte) Ltd and - Forefront Medical Investment Pte. Ltd. in Singapore - Forefront (Xiamen) Medical Devices Co., Ltd and - Forefront Medical Technology (Jiangsu) Co., Ltd in China - and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore. A quote from 1st half financial report: full medical devices for an increasing number of medical industry segments such as - Airway Management, - Respiratory, Endoscopy, - Drug Delivery and - Vascular. Also, the segment has shown substantial depth of experience and expertise that gives its global customers the confidence to place orders with it for the manufacturing of their medical devices. Just sharing. Dyodd
Useful To Me  Not Useful To Me
josephyeo Elite	28-Jan-2020 14:24        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	Company is very much exposed in China. I believe the demand for the medical devices likely to be very good given the current health issues in China. Just my views. I could be wrong. josephyeo      ( Date: 28-Jan-2020 14:18) Posted: A quote from company' s annual report: The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries, Forefront Medical Technology (Pte) Ltd and Forefront Medical Investment Pte. Ltd. in Singapore Forefront (Xiamen) Medical Devices Co., Ltd and Forefront Medical Technology (Jiangsu) Co., Ltd in China and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore.   A quote from 1st half financial report:   full medical devices for an increasing number of medical industry segments such as - Airway Management, - Respiratory, Endoscopy, - Drug Delivery and - Vascular. Also, the segment has shown substantial depth of experience and expertise that gives its global customers the confidence to place orders with it for the manufacturing of their medical devices. Just sharing. Certainly
Useful To Me  Not Useful To Me
josephyeo Elite	28-Jan-2020 14:18        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	A quote from company' s annual report: The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries, Forefront Medical Technology (Pte) Ltd and Forefront Medical Investment Pte. Ltd. in Singapore Forefront (Xiamen) Medical Devices Co., Ltd and Forefront Medical Technology (Jiangsu) Co., Ltd in China and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore.   A quote from 1st half financial report:   full medical devices for an increasing number of medical industry segments such as - Airway Management, - Respiratory, Endoscopy, - Drug Delivery and - Vascular. Also, the segment has shown substantial depth of experience and expertise that gives its global customers the confidence to place orders with it for the manufacturing of their medical devices. Just sharing. Certainly
Useful To Me  Not Useful To Me
josephyeo Elite	24-Jan-2020 23:04        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	A quote from the company: The medical devices segment has evolved significantly since FY2013. Its focus is still 100% on the medical devices sector but rather than having most of its revenue derived from a single customer for a single family of products in a single medical industry segment, it now has a much broader range of customers in different locations and manufactures a much wider range of products from components to full medical devices for an increasing number of medical industry segments such as Airway Management, Respiratory, Endoscopy, Drug Delivery and Vascular. Also, the segment has shown substantial depth of experience and expertise that gives its global customers the confidence to place orders with it for the manufacturing of their medical devices. Over the last six years (including FY2019) the segment has focused on improvements in the following areas: &bull Building more and better capabilities to provide customers with the products, services and people needed to give them the right solutions, all under one roof &bull Investing in automation to improve plant utilisation and efficiency &bull Investing in training to build a highly proactive and experienced team with the right technical expertise and high engagement in the business &bull Expanding into electro-mechanical design and manufacture &bull Faster and more effective collaborative project commercialisation Certainly, there will be challenges along the way. At this moment, the key challenge is the uncertainty arising from the ongoing trade tensions between the major economies. The segment continues to monitor this situation very closely and will expand its Singapore manufacturing operations to provide a greater range of manufacturing options to customers. In summary, the medical devices segment has charted its clear and consistent direction for achieving growth over the long term. It will continue to improve capabilities and operational efficiency in order to be a strategic manufacturing partner to global product owners in the medical devices industry. Whether new business opportunities are found in more efficient manufacturing of an existing mature product or scaling up manufacturing of a new product design, the medical devices segment is poised to offer its customers the right solutions for their medical devices projects.
Useful To Me  Not Useful To Me
josephyeo Elite	23-Jan-2020 23:35        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	3 main reasons why i am vested in this counter: 1. excellent dividend yield       full year dividend 0.75 cts, price 9.0 cts ... yield 8.3% 2. low valuation     on profit of $4.2 mil against market cap of $45.6 mil, the p/e is 10.8 X.     This is relatively low considering the fact that it has a growing medical     devices sector n its high dividend yield 3. its like to be a growth company     Its efforts in the expansion of the medical devices segment seem to     bear fruits. It has widened its customer base, introduce more products     and gone into more segments of the medical industry. Example, they     are now in Airway Management, Respiratory, Endoscopy, Drug Delivery     and Vascular. As company is thinly traded, this counter is not for punters/traders. Its more for long term holder or dividend investors. Just sharing. Dyodd
Useful To Me  Not Useful To Me
josephyeo Elite	23-Jan-2020 00:09        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	Vicplas International has been in the market for 21 years. Its IPO at 13.2 cts was on 22nd April 1999.   It&rsquo s a thinly traded company, often with a wide gap between buyers n sellers. Its an off radar stock w hardly any investor interest.   Company has been profitable in the past years. The profits in the last 3 years have been encouraging with $3.2 mil for year 2017, $2.9 mil in year 2018 and $4.2 in 2019.    I sense that the profits are likely to improve further, given that the company has put more emphasis on its medical devices sector. Of late, they have broaden its customer base. It has also increase its range of products and are now able to cater to different segments of the medical industry. Some of the segments are - Airway Management, Respiratory, Endoscopy, Drug Delivery and Vascular.The results have been reflected in the latest financial year when the company registered a profit of $4.2 mil.   At 9.1 cts, the company is trading on a p/e (price earning ratio) of around 10 X which is " cheap" relative to other companies  in the segment.   Company has been consistent in its dividend. It has declared a dividend of 0.75 cts each year for the past 5 years. This works out to be a yield of 8 plus percent on current price of 9.1 cts.   The company will be reporting its half year result around  mid March 2020.    Look forward to its result.   Am vested. Just sharing my thoughts. Dyodd.
Useful To Me  Not Useful To Me
josephyeo Elite	22-Jan-2020 17:54        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	Vicplas is one of the highest dividend yield company for the past 5 years.
Useful To Me  Not Useful To Me
josephyeo Elite	22-Jan-2020 16:07        josephyeo About Contact  Quote this Post! Style: Fundamental
x 0   x 0  Alert Admin	Share some notes on Vicplas International. Vicplas has been a profitable company for the past years. See below:   vicplas FY' 16 FY' 17 FY' 18 FY' 19 revenue 76104 63,710 68,673 80,165 net profit 5,381 3,206 2,950 4,236 The company has consistently distributed dividends of 0.75 cts per year for the last 5 years. This give a yield of 8.2% on the last closing price of 9.1 cts. Just sharing. Am vested for the excellent dividend.
Useful To Me  Not Useful To Me

                                                         First   < Newer   81-96 of 96   Last